MS Clinical Trials

Find MS Clinical Trials Near You

Name: Active Multiple Sclerosis Clinical Trials in the United States
Creator: MS Buddy
License: https://clinicaltrials.gov/about-site/terms-conditions

Active MS trials registered on ClinicalTrials.gov with U.S. sites, searchable by location, phase, and drug. Eligibility is determined by each trial's criteria and your neurologist, so treat this directory as a starting point, not a screening tool.

577 active trials

381 recruiting now

48 U.S. states

Browse by phase

Phase 1

Safety and dosing in a small group

43 trials

Phase 2

Early evidence that a treatment works

60 trials

Phase 3

Large trials that regulators use to decide on approval

49 trials

Phase 4

Post-approval studies of an existing treatment

19 trials

Featured Phase 3 & 4 trials recruiting now

Late-stage trials enrolling new participants

RecruitingPhase 3

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

Ublituximab · Ublituximab

360 participantsDetails ›

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

Browse by state

Active MS trials across 48 states

All MS trials

Showing 24 of 577 trials

Closed to new patientsPhase 2

HB-adMSCs for the Treatment of Patients With Multiple Sclerosis

Sponsor: Hope Biosciences Research Foundation

Autologous HB-adMSCs

1 state10 participantsDetails ›

Closed to new patientsNA

A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis

Sponsor: University of California, San Francisco

MS CATCH

1 state100 participantsDetails ›

Closed to new patientsNA

A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.

Sponsor: St. Olavs Hospital

Digital Cognitive Behavioral Therapy … · Digital patient education about insom…

550 participantsDetails ›

Closed to new patientsNA

A Health Action Process Approach Online Intervention for People With Multiple Sclerosis

Sponsor: University of Illinois at Urbana-Champaign

MSPA eClass

1 state60 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patients

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

Sponsor: Celestra Health Systems

1 state90 participantsDetails ›

Closed to new patients

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Sponsor: Bristol-Myers Squibb

1 state9000 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patients

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Sponsor: Biogen

Natalizumab

1 state400 participantsDetails ›

Closed to new patientsPhase 1

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Sponsor: Bruce Cree

KYV-101 (Biological) - 0.33 ×10^8 cells · KYV-101 (Biological) - 1 ×10^8 cells

1 state10 participantsDetails ›

Closed to new patientsPhase 2

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Sponsor: Eli Lilly and Company

LY3541860 · Placebo

5 states63 participantsDetails ›

Closed to new patientsPhase 2

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Sponsor: Zenas BioPharma (USA), LLC

Obexelimab · Placebo

11 states93 participantsDetails ›

Closed to new patientsPhase 2

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

5 states23 participantsDetails ›

Closed to new patientsPhase 4

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Sponsor: Bristol-Myers Squibb

BMS-986374

84 participantsDetails ›

Closed to new patients

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Sponsor: Bristol-Myers Squibb

200 participantsDetails ›

Closed to new patients

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Sponsor: Biogen

Diroximel Fumarate · Dimethyl Fumarate

1 state10500 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsNA

A Study to Evaluate White Matter Hyperintensities in Migraine

Sponsor: Mayo Clinic

Brain Neuroimaging

1 state50 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab · Placebo

5 states1013 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Page 1 of 25

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.